CopyMark Law Group
4.9/5
Drawing for BP BALKAN PHARMACEUTICALS

USPTO serial 79272941

BP BALKAN PHARMACEUTICALS

Reviewed by CopyMark Law Group

Reg. 6166331Status 700Renewal
Filing date
Status date
Registration date
Oct 6, 2020
Examiner
SEVERSON, JUSTIN
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with BP BALKAN PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $425

Trademark Monitoring(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Bruce S. Londa

Bruce S. Londa Norris McLaughlin P.A.7 Times SquareNew York, NY 10036-6524UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical, medical and veterinary products, namely, products for treating digestive maladies and for affecting metabolism namely, antacids, antiulcerous preparations, antiflatulence preparations; antispastics, anticolinergics, antipropulsives; antivomitive and antinauseants, antidiarrheals; digestive aids, namely, food enzyme and dietary supplements; metabolic aids, namely, stanozolol, methandienone, mesterolone, oxandrolone and nandrolone; products for treating the liver, namely, lipotropics; products for treating disorders and illnesses of blood, haematopoetic organs- and the heparin group, namely, platelet antiaggregants; products for treating disorders and illnesses of the cardiovascular system and for providing heart therapy, namely, diuretics, peripherical vasodilators; blockers, namely, bisoprolol, pantoprazole, famotidine and naltrexone; products that act on the renin-angiotensin system, namely, ramipril, lizinopril, enalapril and captoprile; pharmaceuticals, namely, lipid lowering agents; genital-urinary system and sexual hormones, sexual and modulator hormones of the genital system, genital system medications; systemic hormonal preparations; antiinfectious products for systemic use, namely, ofloxacine, metronidazole, acyclovir, amoxaciline and furaciline; antineoplastic agents and immunomodulators; products for treating the skeletal muscle system, namely, antiinflammatory and antirheumatic non-steroids; products for treating the nervous system, namely, anesthetics, anticonvulsants, antiemetics, antiparkinson agents, CNS stimulants, muscle relaxants, narcotic analgesics, nonnarcotic analgesics, and sedatives; antiparasitics; products for treating the breathing pathway, namely, antiasthmatics, systemic antihistamines; sanitary products for medical use, namely, absorbent products for personal health care and hygiene, medical disinfectant liquids, wipes, sprays and soapsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 6, 2025REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Mar 1, 2021FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 28, 2021XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Jan 28, 2021XXCRGENERIC MADRID TRANSACTION CREATED—
Jan 6, 2021FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 6, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 31, 2020GPNXNOTIFICATION PROCESSED BY IB—
Jul 21, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 21, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 15, 2020OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 15, 2020OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 1, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 17, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 20, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 19, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 19, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 24, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 24, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 24, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 26, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 26, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 26, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 22, 2020RFNTREFUSAL PROCESSED BY IB—
Feb 5, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 5, 2020RFRRREFUSAL PROCESSED BY MPU—
Jan 11, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 10, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 10, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 3, 2020DOCKASSIGNED TO EXAMINER—
Dec 6, 2019MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 2, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 28, 2019REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance